Lilly, Rigel To Develop RIPK1 Inhibitors For Treatment Of Immunological & Neurodegenerative Diseases
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) and Rigel Pharmaceuticals Inc. (RIGL) said that they have collaborated to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein
Eli Lilly Rigel Pharmaceuticals Inc Rigel Pharmaceuticals எலி லில்லி கடுமையான மருந்துகள் இன்க் கடுமையான மருந்துகள்
Source: finanznachrichten.de